PanBRCA™ Inherited Breast & Ovarian Cancer Screening Test

EARLY DETECTION, EARLY DIAGNOSIS AND EARLY TREATMENT

Breast cancer is the THIRD most deadly cancer among women in Hong Kong, second only to lung cancer and colorectal cancer. In 2018 alone, a total of 753 women died of breast cancer, accounting for 12.4% of female cancer deaths. Breast cancer also happens occasionally in men. In 2017, there were 18 new cases of male breast cancer.

•According to the latest 2020 study, it is estimated that more than 5 million people in China carry BRCA disease-causing gene mutations
 
•And taking Asians as an example, the presence of a disease-causing mutation in the BRCA gene represent a 87% chance of developing breast cancer, a 44% chance of developing ovarian cancer and also an increased risk for other types of cancer (such as pancreatic cancer, colorectal cancer, prostate cancer etc.) during their lives. Most cancer types show no symptoms in early stage. Thus, most patients are already in late stages when they are diagnosed with cancers, which greatly increases the difficulty of treatment.

Specifically designed for Asians - common Asian-specific gene mutations

·Using next-generation sequencing (NGS) and the most advanced technology to detect any genetic mutations, including gene rearrangements and large deletions of BRCA1&2 genes, related to hereditary breast cancer and ovarian cancer.
 
·PANGENIA's Breast Cancer and Ovarian Cancer Screening (BRCA1&2) is designed for screening Asian genetic mutations, with a coverage up to 95%.
 
 
High Accuracy - Trustworthy Bioinformatics
 
·PanBRCA™ uses advanced data analysis technology to achieve a higher detection coverage and analytical sensitivity than most other BRCA tests in the market. A confirmatory test will be performed in dual to ensure the highest accuracy.
 
***This screening test is highly rated with exceptional performance in the Proficiency testing program provided by the College of American Pathologist (CAP)***

 

PanBRCA™ Screening Test Features

Is the test right for me?

If you belong to any below group, it is suggested to do this test.

• Early onset breast cancer(<45years old)
• Bilateral or multiple primary breast cancers
• Male breast cancer at any age
• Breast and ovarian cancer in the same women
• 3 or more cases of breast cancer in the family
• 3 or more cases of breast, ovarian and/or pancreatic cancer in the family
• 3 or more cases of breast, uterine and/or thyroid cancer in the family
• Multiple close family members with breast and other cancers

PanBRCA™ Screening Test Procedure

·Collect samples by drawing 6ml EDTA blood or 10 buccal swabs
·TAT: within 14-20 working days
·100% Hong Kong local laboratory, analysis and professional test report
·Professional report interpretation provided by genetics consultant

Test Specifications

Test Code
Methodology
Specimen Requirements
Turnaround Time
OBS
Next generation sequencing (NGS)
6 mL blood in EDTA tube or 10 Buccal Swab
14-20 working days
OBF
Next generation sequencing (NGS)
6 mL blood in EDTA tube or 10 Buccal Swab
14-20 working days

What should I do if my test results are positive?

If you you get a negative result, it does not mean you are not under the risk of cancer. Please consult your physicians or genetic counselor for professional advices before taking any actions.

Sharing the result with family members. If the person carriers BRCA mutation(s), her/his family member has 50% chance inherits the same mutation(s). Telling them might help them decide if they should get tested or adopt some of the approaches to try to lower their risk.

Frequently asked questions (FAQs)

Q: What is PanBRCA™ Inherited Breast & Ovarian Cancer Screening Test?
A: Through next-generation sequencing technology (NGS) to check whether there are BRCA1 or BRCA2 gene mutations for more detailed disease risk assessment.
 
Q: Why do need to perform PanBRCA™ Inherited Breast & Ovarian Cancer Screening Test?
A: PanBRCA™ Inherited Breast & Ovarian Cancer Screening Test can achieve early prevention, early detection, and early treatment of related cancers, which is especially important for high-risk individuals.
 
Q: What is the possible benefits of PanBRCA™ Inherited Breast & Ovarian Cancer Screening Test?
A: Early understanding of the risk of hereditary breast cancer, ovarian cancer and related cancers can help improve the effectiveness of prevention and treatment.

How to get started

Our tests must be ordered by a doctor. Ask your doctor if a Mygenia test is right for you. We can help you find a doctor if you don’t have one.

I have a doctor
References
Reference
1. E.R. Copson et al. (2018). Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 19:169-180
2. K. Alsop et al. (2012). BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 30(21):2654-2663
3. D.J. Gallagher et al. (2010). Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer. Clinical Cancer Research. 16(7):2115-2121
4. B.L. Niell et al. (2004). BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer. Journal of the National Cancer Institute. 96(1):15-21
5. S. Holter et al. (2015). Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Journal of Clinical Oncology. 33(28):3124-3129
6.Department of Health(HKSAR)
7. Dong, H., Chandratre, K., Qin, Y., Zhang, J., Tian, X., Rong, C., Wang, N., Guo, M., Zhao, G. and Wang, S., 2020. Prevalence of BRCA1/BRCA2 pathogenic variation in Chinese Han population. Journal of Medical Genetics, pp.jmedgenet-2020-106970.